[HTML][HTML] Lymphatic dysfunction attenuates tumor immunity through impaired antigen presentation

T Kimura, M Sugaya, T Oka, A Blauvelt, H Okochi… - Oncotarget, 2015 - ncbi.nlm.nih.gov
T Kimura, M Sugaya, T Oka, A Blauvelt, H Okochi, S Sato
Oncotarget, 2015ncbi.nlm.nih.gov
Tumor growth and metastasis of cancer involve autonomous tumor cell growth and host-
tumor interactions. While tumor-specific immunity has been intensively studied in vitro,
dynamic roles of lymphatic transport on tumor immunity in vivo have not been fully
elucidated. In this study, we examined tumor growth and anti-tumor immune responses
using kCYC mice, which demonstrate severe lymphatic dysfunction. Primary tumor growth
was augmented in kCYC mice (compared to wild-type mice) when B16 melanoma or EL-4 …
Abstract
Tumor growth and metastasis of cancer involve autonomous tumor cell growth and host-tumor interactions. While tumor-specific immunity has been intensively studied in vitro, dynamic roles of lymphatic transport on tumor immunity in vivo have not been fully elucidated. In this study, we examined tumor growth and anti-tumor immune responses using kCYC mice, which demonstrate severe lymphatic dysfunction. Primary tumor growth was augmented in kCYC mice (compared to wild-type mice) when B16 melanoma or EL-4 lymphoma cells were subcutaneously injected. Expression of inflammatory cytokines such as IFN-γ, TNF-α, and IL-2 as well as IL-10 expression in draining lymph nodes (LNs) was significantly reduced in kCYC mice after tumor inoculation. Moreover, decreased levels of tumor-associated antigens were detected in draining LNs in kCYC mice, together with impaired antigen presentation. CD8+ T cells in draining LNs derived from kCYC mice bearing B16 melanoma also showed significantly decreased cytotoxic activity in vitro. Finally, tumor suppression activity of CD8+ T cells derived from kCYC mice bearing B16 melanoma was reduced when adoptively transferred to naive wild-type mice. In summary, these findings suggest that lymphatic transport is essential in generating optimal tumor-specific immune responses mediated by CD8+ T cells.
ncbi.nlm.nih.gov